Change in the neutrophil-lymphocyte ratio may predict early recurrence in operated bladder cancer

被引:1
作者
Colak, Rumeysa [1 ,3 ]
Erdem, Gokmen Umut [2 ]
Kapar, Caner [1 ]
Gulturk, Ilkay [1 ]
Aksu, Faruk [2 ]
Erdal, Gulcin Sahingoz [1 ]
Yilmaz, Mesut [1 ]
Tural, Deniz [1 ]
机构
[1] Bakirkoy Dr Sadi Konuk Training & Res Hosp, Dept Med Oncol, Istanbul, Turkiye
[2] Basaksehir Cam & Sakura City Hosp, Dept Med Oncol, Istanbul, Turkiye
[3] Univ Hlth Sci, Bakirkoy Dr Sadi Konuk Training & Res Hosp, Dept Med Oncol, Dr Tevfik Saglam St 11, TR-34147 Istanbul, Turkiye
关键词
bladder cancer; disease-free survival; neutrophil-lymphocyte ratio; recurrence; urothelial carcinoma; GLASGOW PROGNOSTIC SCORE; UROTHELIAL CARCINOMA; PRETREATMENT NEUTROPHIL; RISK STRATIFICATION; RADICAL CYSTECTOMY; SURVIVAL; INFLAMMATION; CHEMOTHERAPY; OUTCOMES; NLR;
D O I
10.1111/ajco.14065
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Recurrence develops in 50% of operated bladder cancer patients. It is important to detect recurrence in advance, and there is no prognostic reliable biomarker for bladder cancer. Objective: The aim of this study is to show that changes in hematological parameters before radiological imaging can predict recurrence. Methods: We performed a retrospective cohort study of patients undergoing radical cystectomy for urothelial carcinoma of the bladder identified using our institutional database (2010-2022). Disease-free survival (DFS) was evaluated as relapse or death due to any cause. Kaplan-Meier analysis was used for DFS according to the follow-up period. DFS was calculated in two groups neutrophil-lymphocyte ratio (NLR) < 3 and NLR >= 3. Log-rank test was used for comparison between groups and p < 0.05 was considered statistically significant. Results: In the study, 91 patients were examined. The median age was 61.0 (34-79). 57.1% of the patients were T (1-2) and 42.9% were T (3-4). The lymph node (LN) was negative in 78% and positive in 22%. Median follow-up time and DFS were 53.4 months and 54%, respectively. The median NLR was 2.8 (0.8-8.7). For DFS, there was a significant difference according to age, T stage, and LN status (p: 0.048, 0.019, and 0.040). There was no significant difference in the NLR in terms of DFS at the time of diagnosis (p: 0.654). In follow-ups; While there was no difference in the NLR for DFS 12 months before recurrence (p: 0.231), there was a significant difference 6 months before the relapse and at the time of recurrence (p: 0.023 and 0.031). Conclusion: The change in the NLR before radiological recurrence in bladder cancer is significant in predicting recurrence. Prospective and multi-center research is needed to confirm our findings.
引用
收藏
页码:199 / 203
页数:5
相关论文
共 35 条
[1]   Usefulness of the Neutrophil-to-Lymphocyte Ratio in Predicting Short- and Long-Term Mortality in Breast Cancer Patients [J].
Azab, Basem ;
Bhatt, Vijaya R. ;
Phookan, Jaya ;
Murukutla, Srujitha ;
Kohn, Nina ;
Terjanian, Terenig ;
Widmann, Warren D. .
ANNALS OF SURGICAL ONCOLOGY, 2012, 19 (01) :217-224
[2]   Inflammation and cancer: back to Virchow? [J].
Balkwill, F ;
Mantovani, A .
LANCET, 2001, 357 (9255) :539-545
[3]  
Celik O, 2016, EUR REV MED PHARMACO, V20, P652
[4]   Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment [J].
Cho, HanByoul ;
Hur, Hye Won ;
Kim, Sang Wun ;
Kim, Sung Hoon ;
Kim, Jae Hoon ;
Kim, Young Tae ;
Lee, Kook .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2009, 58 (01) :15-23
[5]   Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer [J].
Chua, W. ;
Charles, K. A. ;
Baracos, V. E. ;
Clarke, S. J. .
BRITISH JOURNAL OF CANCER, 2011, 104 (08) :1288-1295
[6]   Systemic inflammation, as measured by the neutrophil/lymphocyte ratio, may have differential prognostic impact before and during treatment with fluorouracil, irinotecan and bevacizumab in metastatic colorectal cancer patients [J].
Formica, Vincenzo ;
Luccchetti, Jessica ;
Cunningham, David ;
Smyth, Elizabeth C. ;
Ferroni, Patrizia ;
Nardecchia, Antonella ;
Tesauro, Manfredi ;
Cereda, Vittore ;
Guadagni, Fiorella ;
Roselli, Mario .
MEDICAL ONCOLOGY, 2014, 31 (09) :1-8
[7]   Decreased Overall and Bladder Cancer-Specific Mortality with Adjuvant Chemotherapy After Radical Cystectomy: Multivariable Competing Risk Analysis [J].
Froehner, Michael ;
Koch, Rainer ;
Heberling, Ulrike ;
Novotny, Vladimir ;
Oehlschlaeger, Sven ;
Huebler, Matthias ;
Baretton, Gustavo B. ;
Hakenberg, Oliver W. ;
Wirth, Manfred P. .
EUROPEAN UROLOGY, 2016, 69 (06) :984-987
[8]   Preoperative anemia is associated with adverse outcome in patients with urothelial carcinoma of the bladder following radical cystectomy [J].
Gierth, M. ;
Mayr, R. ;
Aziz, A. ;
Krieger, S. ;
Wullich, B. ;
Pycha, A. ;
Lodde, M. ;
Salvadori, U. ;
Bruendl, J. ;
Fritsche, H. M. ;
Hofstaedter, F. ;
Pawlik, M. T. ;
Otto, W. ;
May, M. ;
Burger, M. ;
Denzinger, S. .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2015, 141 (10) :1819-1826
[9]   Prognostic Value of Neutrophil-to-lymphocyte Ratio and Establishment of Novel Preoperative Risk Stratification Model in Bladder Cancer Patients Treated With Radical Cystectomy [J].
Gondo, Tatsuo ;
Nakashima, Jun ;
Ohno, Yoshio ;
Choichiro, Ozu ;
Horiguchi, Yutaka ;
Namiki, Kazunori ;
Yoshioka, Kunihiko ;
Ohori, Makoto ;
Hatano, Tadashi ;
Tachibana, Masaaki .
UROLOGY, 2012, 79 (05) :1085-1091
[10]   Immunity, Inflammation, and Cancer [J].
Grivennikov, Sergei I. ;
Greten, Florian R. ;
Karin, Michael .
CELL, 2010, 140 (06) :883-899